New combo therapy aims to control brain metastases in lung cancer patients

NCT ID NCT07505173

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Apr 08, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This study tests a new treatment for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has spread to the brain and is causing symptoms. The treatment combines a targeted pill (osimertinib) with a precise form of whole-brain radiation that protects the memory center (hippocampus). The goal is to better control the brain tumors while reducing side effects and preserving quality of life. About 74 participants will be enrolled to see how long the cancer stays under control in the brain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAIVE ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS (EGFR EXON 19 DELETION AND EXON 21 L858R MUTATION) AND SYMPTOMATIC BRAIN METASTASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, China

Conditions

Explore the condition pages connected to this study.

NAIVE ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS (EGFR EXON 19 DELETION AND EXON 21 L858R MUTATION) AND SYMPTOMATIC BRAIN METASTASES